4
ANZUP ANNUAL REPORT 2016
CHAIRMAN’S REPORT
On behalf of the Board I am pleased to report to you ANZUP’s activities over the last year.
active trial (SORCE) is now in follow-up. We have trials in early and advanced disease; treatment naive and treatmentrefractory populations; driven by medical oncologists, urologists, radiation oncologists, or psychologists.
ANZUP’s vision is “to minimise the effect of prostate and other urogenital cancer on the community in terms of Our trials include translational components, quality of life and survival, incidence and quality of life, through research and supportive care aspects, and health economic endpoints. The education and by providing patients and carers with support.” trials range from small singleThis statement contains the arm studies through to very recognition that our work includes “...to minimise the effect of large international randomised but is not limited by clinical trials phase 3 trials. This year we have of conventional intervention prostate and other urogenital commenced the BL.12 trial in strategies, while also providing urothelial cancer, in conjunction cancer on the community in for the many other types of work with the Canadian Cancer Trials we do, which leads to the same terms of survival, incidence and Group. We have also commenced end of improved outcomes for the Pain Free TRUS B trial of our patients and their families. quality of life, through research methoxyflurane in prostate biopsy, and education and by providing The ANZUP Strategic Plan for funded by Cancer Australia and 2013-2015 outlined several Prostate Cancer Foundation of patients and carers with support.” the key areas of activity and we Australia. have made very significant ANZUP’s work is now recognised on the international stage. progress towards achieving all of these goals. Some of However, we have only just begun and much work remains the key strategic areas in broad terms were as follows: to be done to meet our vision. Each trial we perform requires 1. Clinical trials resources including substantial funding. Across all the disease types we represent, ANZUP currently has clinical trials active in prostate, urothelial, testicular / germ cell and renal cell carcinomas. These trials are actively accruing in all these areas except renal cell carcinoma where our current
Our eventual aim is to become less dependent on external funders to support our own clinical trials. The success of initiatives such as the Below the Belt Pedalthon is a first step
